<DOC>
	<DOC>NCT00604630</DOC>
	<brief_summary>The purpose of this randomized, double-blind, placebo-controlled multicenter study is to determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment on functional outcome up to a follow-up of 90 days.</brief_summary>
	<brief_title>Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Ischemic stroke in the middle cerebral artery territory Clearly defined time of onset Confirmed by MRI (DWI, Flair) NIH Stroke Scale ≥ 5 Age &gt; 18 years Treatment within 6h after onset of symptoms Informed consent by patient, relatives or independent physician Life expectancy &gt; 90 days Coma or precoma (level of consciousness ≥ 2 in NIH Stroke Scale) Previous stroke within the same territory Intracranial or subarachnoidal hemorrhage Traumatic brain injury or brain operation within the last 4 weeks Neoplasia, septic embolism, infectious endocarditis MRI contraindications Renal failure (i.e. dependent on dialysis) Known malignant/lifethreatening disease Known myeloproliferative disorder, polycythemia Known allergy or antibodies against erythropoietin Participation in other intervention trials Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>stroke</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>ischemia</keyword>
	<keyword>hypoxia</keyword>
	<keyword>antiapoptosis</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>rtPA</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>stroke, middle cerebral artery</keyword>
	<keyword>Ischemic stroke in the middle cerebral artery territory</keyword>
</DOC>